Compare Abbott Laboratories (ABT) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs McCormick & Company, Incorporated — how do they compare? Abbott Laboratories trades at $95.43 (market cap $166.94B), while McCormick & Company, Incorporated trades at $51.81 (market cap $14.04B). The key difference: Abbott Laboratories is far larger — about 11.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| ABT | MKC | |
|---|---|---|
Market Cap | $166.94B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $72.90 |
52-Week Low | $82.57 | $45.60 |
Enterprise Value | $193.69B | $18.64B |
Dividend Yield | 2.63% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
McCormick (MKC) trades at $52.22, down 2.3% today but maintains a bullish technical outlook with strong support at $51. The company delivered solid Q2 2026 results with earnings of $0.80 per share beating estimates, driven by 14% constant currency sales growth and margin expansion to 40.2%. Valuation metrics appear attractive with a P/E of 8.62 and P/S of 1.89, while analyst consensus targets $59.67 representing 14% upside potential.
The investment case centers on MKC's defensive positioning in consumer staples, transformative Unilever food business combination potential, and improving profitability. Key risks include soft consumer volume trends in the Americas and execution challenges from the pending acquisition. With 36.7% of analysts rating the stock a buy and institutional ownership stable, MKC offers value with a 4% dividend yield amid ongoing operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
